Kiromic BioPharma's Prioritizes New Gamma Delta T-Cell Product Candidate

• Kiromic BioPharma Inc (NASDAQ: KRBP) has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT.

• Kiromic expects to submit its first new investigational new drug (IND) application to the FDA in 2H of 2022.

• The IND will seek to evaluate Deltacel in combination with a standard antitumor modality, with the expected beginning of trial activation by year-end.

• Related: Why Kiromic Biopharma Shares Are Skyrocketing Today?

• Kiromic will also pursue INDs for its Procel and Isocel product candidates in combination with a standard antitumor modality in 2023.

• These three additional IND filings will expand the Company's pipeline to five allogeneic GDT clinical trials and three product candidates.

• Price Action: KRBP shares are up 14.60% at $0.46 during the market session on the last check Tuesday.

See more from Benzinga

• TPG Capital Takes Healthcare Technology Convey Health Private In $1B Deal

• FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.